GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 3

Completed

Conditions: Gastric Adenocarcinoma

Interventions: Drug: Placebo
Drug: Andecaliximab
Drug: Leucovorin
Drug: 5-fluorouracil
Drug: Oxaliplatin

First Posted Date: 2015-09-10

Last Posted Date: 2020-05-26

Lead Sponsor: Gilead Sciences

Target Recruit Count: 432

Registration Number: NCT02545504

Locations: 🇨🇱
Instituto Clinico Oncologico del Sur, Temuco, Chile
🇵🇪
Centro Medico monte Carmelo, Arequipa, Peru
🇦🇺
The Canberra Hospital, Garran, Australian Capital Territory, Australia

and more 131 locations

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: Idelalisib
Drug: BI 836826

First Posted Date: 2015-09-02

Last Posted Date: 2020-11-25

Lead Sponsor: Gilead Sciences

Target Recruit Count: 2

Registration Number: NCT02538614

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States

Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF
Drug: COPE

First Posted Date: 2015-09-01

Last Posted Date: 2017-06-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 552

Registration Number: NCT02537379

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Phase 3

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: Idelalisib

First Posted Date: 2015-08-31

Last Posted Date: 2023-08-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 96

Registration Number: NCT02536300

Locations: 🇬🇧
Barts Health Trust, London, United Kingdom
🇨🇿
Fakulni newmcince v Motole, Onkologicka klinika 2. LF UK a FN Motol, Praha 5, Czechia
🇦🇺
Calvary Norht Adelaide Hosptial, Woodville South, South Australia, Australia

and more 63 locations

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL/VOX
Drug: RBV

First Posted Date: 2015-08-31

Last Posted Date: 2019-02-25

Lead Sponsor: Gilead Sciences

Target Recruit Count: 49

Registration Number: NCT02536313

Locations: 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States

Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Phase 2

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Drug: Placebo
Drug: Presatovir

First Posted Date: 2015-08-27

Last Posted Date: 2018-11-28

Lead Sponsor: Gilead Sciences

Target Recruit Count: 61

Registration Number: NCT02534350

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: SOF/VEL/VOX
Drug: VOX
Drug: Norgestimate/ethinyl estradiol

First Posted Date: 2015-08-26

Last Posted Date: 2020-09-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 15

Registration Number: NCT02533427

Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function

Phase 1

Completed

Conditions: Oncology

Interventions: Drug: Entospletinib

First Posted Date: 2015-08-13

Last Posted Date: 2019-07-26

Lead Sponsor: Gilead Sciences

Target Recruit Count: 56

Registration Number: NCT02521376

Locations: 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
🇳🇿
Auckland Clinical Studies, Auckland, New Zealand
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 3 locations

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Biological: Andecaliximab
Biological: Placebo

First Posted Date: 2015-08-11

Last Posted Date: 2019-04-10

Lead Sponsor: Gilead Sciences

Target Recruit Count: 165

Registration Number: NCT02520284

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Terminated

Conditions: Hepatitis C Virus Infection

First Posted Date: 2015-07-29

Last Posted Date: 2023-01-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 461

Registration Number: NCT02510300

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

and more 48 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy